HIGHLIGHTS
- who: Maria Moscvin from the Patient population We identified ten consecutive patients who developed TMA between, while receiving treatment with carfilzomib at the University of Athens in Greece or at the Dana Farber Cancer Institute in the United StatesA clinical diagnosis of carfilzomib-induced TMA was made based on the fulfillment of the following criteria: active carfilzomib treatment have published the research: Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy, in the Journal: (JOURNAL) of 13/09/2022
- how: This study was conducted in accordance with the Declaration . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.